



Application No. (if known): 10/616,769

Attorney Docket No.: 66535DIV(46590)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 892898663 US in an envelope addressed to:

MS Assignment Recordation Services
Director of the US Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

on October 26, 2006
Date

Signature

Melissa Altman

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 439-4444
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Response to Restriction Requirement (2 pages)
Recordation Form Cover Sheet (1 page)
Change of Name Document (1 page)
Return Receipt Postcard
Charge \$40.00 to deposit account 04-1105



Docket No.: 66535DIV (46590)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Momose, Yu et al.

Application No.: 10/616,769

Confirmation No.: 3491

Filed: July 10, 2003

Art Unit: 1617

For: NEUROTROPHIN
PRODUCTION/SECRETION PROMOTING
AGENT

Examiner: S. Wang

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed September 26, 2006, applicant hereby provisionally elects Group I, claims 1, 3, 6, 8-12, 15, 29, 30, 32-38, 43 and 45-47 for continued examination, without traverse. The claims are drawn to a method of preventing or treating senile dementia of Alzheimer type comprising administering a compound of the formula in claim 1, wherein X is oxygen.


Applicants make this election without prejudice to pursuance of any original material in a later filed application claiming priority to the instant application. In order to fully comply with the request for restriction election, Applicants elect the species compound of claim 43, 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole.

The Examiner is requested to call Applicants' undersigned representative to discuss the restriction application. Applicants thank the Examiner in advance for this courtesy.

The Director is hereby authorized to charge any credits or deficiency in the fees filed (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. (46590) 66535DIV.

Dated: October 26, 2006

Respectfully submitted,



Gregory B. Butler, PhD, Esq

Registration No.: 34,558

EDWARDS ANGELL PALMER & DODGE

LLP

P.O. Box 55874

Boston, Massachusetts 02205

Attorney/Agent For Applicant